204 related articles for article (PubMed ID: 22563374)
1. Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.
van Luijn MM; van de Loosdrecht AA; Lampen MH; van Veelen PA; Zevenbergen A; Kester MG; de Ru AH; Ossenkoppele GJ; van Hall T; van Ham SM
PLoS One; 2012; 7(4):e34649. PubMed ID: 22563374
[TBL] [Abstract][Full Text] [Related]
2. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
[TBL] [Abstract][Full Text] [Related]
3. Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.
van Luijn MM; Chamuleau ME; Thompson JA; Ostrand-Rosenberg S; Westers TM; Souwer Y; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
Haematologica; 2010 Mar; 95(3):485-93. PubMed ID: 19903675
[TBL] [Abstract][Full Text] [Related]
4. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
5. Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.
van Luijn MM; Chamuleau ME; Ressing ME; Wiertz EJ; Ostrand-Rosenberg S; Souwer Y; Zevenbergen A; Ossenkoppele GJ; van de Loosdrecht AA; van Ham SM
Cancer Immunol Immunother; 2010 Dec; 59(12):1825-38. PubMed ID: 20820776
[TBL] [Abstract][Full Text] [Related]
6. A continuous central motif of invariant chain peptides, CLIP, is essential for binding to various I-A MHC class II molecules.
Weenink SM; Milburn PJ; Gautam AM
Int Immunol; 1997 Feb; 9(2):317-25. PubMed ID: 9040013
[TBL] [Abstract][Full Text] [Related]
7. Modulation of antigen presentation and class II expression by a class II-associated invariant chain peptide.
Zechel MA; Chaturvedi P; Lee-Chan EC; Rider BJ; Singh B
J Immunol; 1996 Jun; 156(11):4232-9. PubMed ID: 8666792
[TBL] [Abstract][Full Text] [Related]
8. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
9. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
Vigna JL; Smith KD; Lutz CT
J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
[TBL] [Abstract][Full Text] [Related]
10. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
11. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
Hitzel C; Koch N
Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
[TBL] [Abstract][Full Text] [Related]
12. Self-release of CLIP in peptide loading of HLA-DR molecules.
Kropshofer H; Vogt AB; Stern LJ; Hämmerling GJ
Science; 1995 Nov; 270(5240):1357-9. PubMed ID: 7481823
[TBL] [Abstract][Full Text] [Related]
13. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading.
van Ham SM; Tjin EP; Lillemeier BF; Grüneberg U; van Meijgaarden KE; Pastoors L; Verwoerd D; Tulp A; Canas B; Rahman D; Ottenhoff TH; Pappin DJ; Trowsdale J; Neefjes J
Curr Biol; 1997 Dec; 7(12):950-7. PubMed ID: 9382849
[TBL] [Abstract][Full Text] [Related]
14. Peptide-dependent expression of HLA-B7 on antigen processing-deficient T2 cells.
Smith KD; Lutz CT
J Immunol; 1996 May; 156(10):3755-64. PubMed ID: 8621911
[TBL] [Abstract][Full Text] [Related]
15. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
[TBL] [Abstract][Full Text] [Related]
16. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM.
Verreck FA; Fargeas CA; Hämmerling GJ
Eur J Immunol; 2001 Apr; 31(4):1029-36. PubMed ID: 11298327
[TBL] [Abstract][Full Text] [Related]
17. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M.
Honey K; Forbush K; Jensen PE; Rudensky AY
J Immunol; 2004 Apr; 172(7):4142-50. PubMed ID: 15034026
[TBL] [Abstract][Full Text] [Related]
18. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
Stumptner P; Benaroch P
EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
[TBL] [Abstract][Full Text] [Related]
19. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
Kropshofer H; Vogt AB; Hämmerling GJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
[TBL] [Abstract][Full Text] [Related]
20. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression.
Antohe I; Tanasa MP; Dăscălescu A; Dănăilă C; Titieanu A; Zlei M; Ivanov I; Sireteanu A; Cianga P
Immunobiology; 2021 Jan; 226(1):152049. PubMed ID: 33352400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
